Edition:
United States

LifeVantage Corp (LFVN.OQ)

LFVN.OQ on NASDAQ Stock Exchange Capital Market

4.08USD
23 Feb 2018
Change (% chg)

$0.18 (+4.62%)
Prev Close
$3.90
Open
$3.91
Day's High
$4.10
Day's Low
$3.91
Volume
5,402
Avg. Vol
10,708
52-wk High
$6.75
52-wk Low
$2.86

Chart for

About

LifeVantage Corporation is a science-based network marketing company. The Company focuses on helping people achieve their health, wellness and financial independence goals. The Company provides products and a financially rewarding direct sales business opportunity to customers and independent distributors seeking a healthy... (more)
No analyst recommendations are available for .

Overall

Beta: 0.35
Market Cap(Mil.): $58.22
Shares Outstanding(Mil.): 14.23
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 21.55 16.59
EPS (TTM): -- -- --
ROI: -- 12.13 35.07
ROE: -- 15.29 17.79

BRIEF-LifeVantage Announces Q2 Earnings Per Share $0.02

* LIFEVANTAGE ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL 2018

Feb 07 2018

BRIEF-Lifevantage Says Products Available For First Time Ever Throughout China

* LIFEVANTAGE CORP - LIFEVANTAGE PRODUCTS AVAILABLE FOR FIRST TIME EVER THROUGHOUT CHINA

Feb 01 2018

BRIEF-Lifevantage Says ‍Providing Notice Of Plaintiffs' Proposed Voluntary Dismissal Of Shareholder Derivative Actions

* LIFEVANTAGE SAYS ‍PROVIDING NOTICE OF PLAINTIFFS' PROPOSED VOLUNTARY DISMISSAL OF SHAREHOLDER DERIVATIVE ACTIONS Source text: (http://bit.ly/2D7WFIx) Further company coverage:

Jan 08 2018

BRIEF-Lifevantage reports $5 mln share repurchase program

* LIFEVANTAGE CORP - ‍EXPECTS TO FUND REPURCHASE PROGRAM THROUGH CASH ON HAND AND FUTURE CASH FLOW FROM OPERATIONS​ Source text for Eikon: Further company coverage:

Nov 27 2017

BRIEF-LifeVantage announces financial results for the first quarter

* LifeVantage announces financial results for the first quarter of fiscal 2018

Nov 08 2017

BRIEF-Lifevantage appoints Kevin Mcmurray as general counsel

* Lifevantage appoints Kevin Mcmurray as general counsel Source text for Eikon: Further company coverage:

Oct 02 2017

BRIEF-Lifevantage Q4 earnings per share $0.01

* Lifevantage announces financial results for the fourth fiscal quarter and full fiscal year 2017

Sep 07 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $132.02 +2.11
AstraZeneca plc (AZN.L) 4,752.00 -20.00
Prestige Brands Holdings, Inc. (PBH.N) $35.15 +0.15
Pfizer Inc. (PFE.N) $36.26 +0.52
Novartis AG (NOVN.S) CHF79.38 -0.60
Merck & Co., Inc. (MRK.N) $54.87 +0.30
Roche Holding Ltd. (ROG.S) CHF222.05 -1.25
Roche Holding Ltd. (RO.S) CHF225.80 -0.60
Abbott Laboratories (ABT.N) $59.71 +0.72

Earnings vs. Estimates